A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Status:
Suspended
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and preliminary efficacy of duvelisib in combination with
pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC).